journal article·2019-04

Studies of a novel hydroxyapatite sustained-release preparation for temozolidomide implantation

Fengbo Yu, Jinghua Wang, Lei Tong, Xiuping Zhang

Publisher page

Abstract

Abstract Nanosized drug delivery systems are promising tools in the field of nanomedicine applied to cancer. A novel temozolidomidehydroxyapatite (TMZ/HAp) sustained-release nanopreparation for implantation in glioblastoma multiforme (GBM) patients was designed, synthesized and characterized in this study. The structure, morphology, drug loading and in vitro delivery properties of the HAp particles and the novel polysuccinimide (PSI)-coated HAp(HAp-PSI) nanoparticles were evaluated using X-ray powder diffraction (XRD), Fourier Transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), transmission electron microscopy (TEM) and high-performance liquid chromatography. The TMZ/HAp-PSI nanoparticles consist of a flower-like HAp core enclosed by a smooth PSI layer, which presents a spherical or nearly spherical form. The TMZ/HAp-PSI nanoparticles further strengthen the encapsulation efficiency to 93.0%. Compared with TMZ/HAp alone, both the TMZ/HAp-PSI nanoparticles and TMZ/HAp-PSI tablets can prolong the drug release time to more than 350 h and avoid an early burst drug release, suggesting a great potential for the brain or bone implantation drug delivery applications.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Bone Tissue Engineering Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (28)

Show source-provided references
1. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance10.1111/cpr.12241 ↗
2. Molecularly targeted therapy for malignant glioma10.1002/cncr.22741 ↗
3. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma10.1056/NEJMoa043330 ↗
4. Assuptions in the radiotherapy of glioblastoma10.1212/WNL.30.9.907 ↗
5. Temozolomide: mechanisms of action, repair and resistance10.2174/1874467211205010102 ↗
6. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy
7. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide10.1200/JCO.2002.20.5.1375 ↗
8. Controllable self-assembly of mesoporous hydroxyapatite10.1016/j.colsurfb.2014.12.055 ↗
9. Conjugation of hydroxyapatite nanocrystals with human immunoglobulin G for nanomedical applications10.1016/j.colsurfb.2011.09.033 ↗
10. Creep behavior of TiBw/Ti and (TiBw + TiCp)/Ti in situ composite10.1023/A:1015770528080 ↗
11. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells10.1016/j.jconrel.2010.07.108 ↗
12. Poly(D,L-lactide-co-glycolide)/hydroxyapatite core-shell nanosphere. Part 2: simultaneous release of a drug and a prodrug clindamycin and clindamycin phosphate10.1016/j.colsurfb.2010.09.012 ↗
13. Study of BSA protein adsorption/release on hydroxyapatite nanoparticles10.1016/j.apsusc.2013.09.027 ↗
14. Hydroxyapatite nanoparticles as vectors for gene delivery10.4155/tde.12.39 ↗
15. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery10.1016/j.pharmthera.2006.05.006 ↗
16. Nanoparticle-mediated treatment of pulmonary arterial hypertension10.1016/B978-0-12-391860-4.00017-3 ↗
17. Injectable porous hydroxyapatite microparticles as a new carrier for protein and lipophilic drugs10.1016/j.jconrel.2005.09.051 ↗
18. Quantifying sustained release kinetics from a polymer matrix including burst effects10.1016/j.memsci.2011.01.050 ↗
19. Surface modification of hydroxyapatite to introduce interfacial bonding with polyactive TM70/30 in a biodegradable composite10.1007/BF00122178 ↗
20. Design and synthesis of novel galactosylated polymers for liposomes as gene drug carriers targeting the hepatic asialoglycoprotein receptor10.1080/10611860801902609 ↗
21. Controlling morphology of hydroxyapatite nanoparticles through hydrothermal microemulsion chemical synthesis10.1016/j.inoche.2012.02.024 ↗
22. Ibuprofen release from porous hydroxyapatite tablets10.1016/j.ceramint.2011.02.021 ↗
23. Hollow carbonated hydroxyapatite microspheres with mesoporous structure: hydrothermal fabrication and drug delivery property10.1016/j.msec.2013.03.040 ↗
24. Hollow hydroxyapatite microspheres: a novel bioactive and osteoconductive carrier for controlled release of bone morphogenetic rotein-2 in bone regeneration10.1016/j.actbio.2013.05.029 ↗
25. A novel drug delivery carrier based on α-eleostearic acid grafted hydroxyapatite composite
26. Knockdown of NOB1 expression by RNAi inhibits cellular proliferation and migration in human gliomas10.1016/j.gene.2013.07.032 ↗
27. P2X7R suppression promotes glioma growth through epidermal growth factor receptor signal pathway10.1016/j.biocel.2013.03.005 ↗
28. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation10.1016/j.stem.2009.11.002 ↗